Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-23
DOI
10.1038/s41598-019-47235-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation between serum galectin-9 levels and liver fibrosis
- (2018) Koji Fujita et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
- (2017) Kostandinos Sideras et al. OncoImmunology
- Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
- (2016) A. Murtaza et al. EUROPEAN JOURNAL OF CANCER
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer
- (2015) Qiu-Xia Qu et al. TUMOR BIOLOGY
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
- (2015) Jie Zhang et al. Thoracic Cancer
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
- (2015) K. M. Mahoney et al. Cancer Immunology Research
- Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells
- (2014) Chuan Wu et al. IMMUNITY
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
- (2013) Christian J. Maine et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease
- (2013) Yuko Kurose et al. BMC Nephrology
- Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C
- (2013) Hassen Kared et al. PLoS Pathogens
- Galectin-9 Acts as a Prognostic Factor with Antimetastatic Potential in Hepatocellular Carcinoma
- (2012) Zhao-Yang Zhang et al. Asian Pacific Journal of Cancer Prevention
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma
- (2012) Elisabetta Cariani et al. PLoS One
- Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection
- (2012) Gaia Nebbia et al. PLoS One
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas
- (2011) Jie Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
- (2011) H. Barrow et al. CLINICAL CANCER RESEARCH
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients
- (2011) Qiyi Zhao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Soluble B7-H1: Differences in production between dendritic cells and T cells
- (2011) Xavier Frigola et al. IMMUNOLOGY LETTERS
- Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
- (2011) Q. Zhao et al. JOURNAL OF IMMUNOLOGY
- Therapeutic potential of Galectin-9 in human disease
- (2011) Valerie R. Wiersma et al. MEDICINAL RESEARCH REVIEWS
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection
- (2010) John A. Mengshol et al. PLoS One
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells
- (2008) J. Klibi et al. BLOOD
- Diagnosis and Treatment of Hepatocellular Carcinoma
- (2008) Hashem B. El-Serag et al. GASTROENTEROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started